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Health systems have improved their abilities to identify, diagnose, treat and, increasingly,
achieve viral suppression among people living with HIV (PLHIV). Despite these advances, a
higher burden of multimorbidity and poorer health-related quality of life are reported by many
PLHIV in comparison to people without HIV. Stigma and discrimination further exacerbate
these poor outcomes. A global multidisciplinary group of HIV experts developed a consensus
statement identifying key issues that health systems must address in order to move beyond
the HIV field’s longtime emphasis on viral suppression to instead deliver integrated, person-
centered healthcare for PLHIV throughout their lives.
Following the introduction of highly effective antiretroviral therapy (ART) in 1996, theglobal scale-up of ART resulted in substantial declines in AIDS-related morbidity andmortality. By the end of 2019, 67% of the world’s estimated 38 million people living with
HIV (PLHIV) had initiated ART, with 59% achieving viral suppression1. The life expectancy for
PLHIV who are diagnosed early and are able to take continuous ART now approaches that of the
general population2. Yet, despite viral suppression, PLHIV often report poor well-being and
health-related quality of life (HRQoL)3–7.
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Factors negatively affecting the HRQoL of PLHIV include
multimorbidity, drug and alcohol dependence, poverty, social
isolation, difficulties disclosing HIV status, and persecution due
to discriminatory laws and attitudes7–14. HIV-related stigma and
discrimination negatively affect the HRQoL of PLHIV through
multiple pathways, including social rejection, low self-esteem, and
barriers to accessing health and support services15–17. These
problems call for a broad health system response to the health-
related needs of PLHIV. This includes the provision of integrated
services for the prevention and management of communicable
and non-communicable diseases, along with psychosocial and
other support to address common psychological, social, and
access challenges. Approaching the healthcare of PLHIV holi-
stically, with decision-making driven by the person’s priorities
rather than by a pathogen-specific paradigm, has the potential to
yield better overall health outcomes18. Comprehensive, multi-
disciplinary healthcare for PLHIV requires an integrated, person-
centered approach. This is likely to enhance HRQoL and con-
tribute to improvements in population-level health across all
domains, including infectious and noncommunicable diseases,
mental health, and sexual and reproductive health.
Achieving consistent, long-term virological suppression has
become a key marker of successful HIV care19,20. Whilst access to
effective ART for all remains essential, it should be seen as one
aspect of a more multifaceted definition of success. The central
goal should be integrated, person-centered healthcare that pro-
motes the importance of HRQoL, recognizing the right of all
people to enjoy “the highest attainable standard of physical and
mental health”21. The World Health Organization (WHO) Global
health sector strategy on HIV 2016–2021 briefly addresses the
non-HIV-specific chronic care needs of PLHIV although without
mention of HRQoL22. UNAIDS has included a general health
target for PLHIV in its strategic guidance for the first time in
2021. It calls for 90% of PLHIV to “have access to integrated or
linked services for HIV treatment and cardiovascular diseases,
cervical cancer, mental health, diabetes diagnosis and treatment,
education on healthy lifestyle counseling, smoking cessation
advice and physical exercise”23. Recently, national and regional
initiatives have promoted a more person-centered HIV care
agenda24,25. This reflects the global movement towards person-
centered care for illness in general. A body of evidence, including
studies of PLHIV, exists to underpin the concept and practice,
which is largely, but not exclusively, from high-income coutries26.
Person-centered healthcare must value the social networks of
patients, promote quality of life, and reform structurally to
improve patients’ experience interacting with the healthcare
system, including respect for and protection of human rights.
However, there is not yet a common understanding of what the
core values and practices of person-centered, holistic care for
PLHIV should encompass, or how aspects of this issue may be
context-specific.
As a first step in achieving a common understanding, a mul-
tidisciplinary expert panel was convened to engage in a Delphi
process to develop a consensus statement on the role of health
systems in advancing the long-term well-being of PLHIV from a
patient-centered perspective. The overarching purpose of the
consensus statement is to guide global, regional, national, and
subnational stakeholders in improving health system responses to
achieve the best possible long-term health outcomes for PLHIV,
including HRQoL outcomes. This article reports on the consensus
development process and the agreed-upon consensus points.
Methodology. We employed a standard six-stage Delphi
process27,28, including the definition of the problem and identi-
fication of experts (Stages 1 and 2, concurrently), three survey
rounds (Stages 3–5), and actions based on the findings (i.e.,
endorsement of consensus statements and recommendations;
Stage 6)29. (Further details of the methodology for this Delphi
study are presented in the Supplementary Information.) The
research team (J.V.L., K.S.) established an expert panel comprised
of 44 individuals with expertise in the long-term health needs of
PLHIV. The expert panel encompassed diverse disciplinary and
geographical perspectives, as well as wide-ranging lived experi-
ences (Table 1, Table 2). Eleven expert panel members, including
two people living openly with HIV, served as members of a
steering committee that was tasked with providing conceptual
guidance for this project (J.A., R.B.L.*, G.B., G.C., N.D.*, M.J.F.,
R.H., A.K.*, J.V.L.*, C.S., K.S.) (project co-chairs denoted by *).
Three teams of steering committee members led scoping reviews
of the literature on multimorbidity (G.B., A.K.), HRQoL (M.J.F.,
R.H.), and stigma and discrimination (J.A., G.C.) in order to
identify priority issues to consider for the consensus statement.
Specifically, the main findings from the respective reviews guided
decision-making regarding potential consensus points. In parti-
cular, issues thought to be difficult to address or inadequately
addressed (e.g., measurement of health-related quality of life,
approaches to addressing stigma) were deemed important by the
steering committee and expert panel members alike to include in
the consensus process.
The research team drew on health system-related issues
identified in the scoping reviews to develop an initial set of 29
proposed consensus points with input from steering committee
members. Expert panel members were then asked to indicate
agreement or disagreement with consensus points in three survey
rounds using the Delphi methodology, with further input
collected via qualitative comments on each draft point. In
addition, their views were sought on selected topics at an online
meeting between the second and third survey rounds.
Results
Overall, agreement consistently increased for the consensus
points across survey rounds, which is likely indicative of the
incorporation of modifications based on the open-ended com-
ments into the final two rounds. In the third survey round, expert
panel members reported unanimous agreement with 22 of the 31
items, and greater than 90% agreement with the remaining nine
items (Table 3). In only three of the final 31 points did we observe
a somewhat different pattern: point 2.4 had a slight shift from
‘Agree’ to ‘Somewhat agree’; point 4.1 had slight shifts from
‘Agree’ and ‘Disagree’ to ‘Somewhat agree’; and point 1.3 had a
slight shift from ‘Agree’ to ‘Disagree.’ For these three points,
however, the aggregate ratings were still strongly in agreement.
(See the Supplementary Information for an explanation of the
consensus grading rubric employed.)
Key terms used in the consensus statement are described in
Box 1. HIV organizations globally were invited to endorse the
final consensus statement (Box 2).
Summary of evidence
Multimorbidity. PLHIV worldwide have a greater burden of
multimorbidity than people without HIV and this burden
increases with age3,30–32. Common comorbidities include hepa-
titis B, hepatitis C, tuberculosis, and aging-associated non-
communicable diseases such as cardiovascular disease, chronic
kidney disease, osteoporosis, and cervical, anal, and other
cancers33–37. Even with access to effective ART, PLHIV are more
likely than people without HIV to experience depression and
other mental health disorders, including substance use
disorders16. Irrespective of whether these conditions precede the
HIV infection, which may affect prevention and treatment,
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multimorbidity in PLHIV is associated with higher levels of
hospitalization38, higher healthcare costs39, higher levels of
polypharmacy40, and lower HRQoL7,13.
Factors contributing to the higher multimorbidity burden in
PLHIV include late diagnosis of HIV, ART toxicities, and long-
term effects of HIV on the immune system41,42. Even among
PLHIV who achieve long-term viral suppression, chronic
immune activation may contribute to the onset of aging-
related comorbidities43,44. Determinants of health,
including social determinants such as poverty, stigma, and
discrimination, as well as environmental factors such as
criminalization and incarceration put some PLHIV at increased
risk of developing comorbidities and having poorer comorbid-
ity outcomes13,45–47. Health-related behaviors such as smoking
and dependent drug or alcohol use further add to the
multimorbidity burden48. Difficulty in disclosing a positive
HIV status, as well as experiences of stigma and discrimination
deeply affect the mental health of PLHIV and introduce barriers
to engagement in care, hence increasing the risk of poor health
outcomes15,49.
Table 1 Expert panel members.
Name Title/affiliation Country of origin
Jane Anderson Consultant Physician, Homerton University Hospital NHS Foundation Trust (United Kingdom) United Kingdom
Ricardo Baptista Leite Member of Parliament, Portuguese National Parliament (Portugal) Portugal
Georg Behrens Professor of Internal Medicine, Medizinische Hochschule Hannover (MHH) (Germany) Germany
Linda-Gail Bekker Director, Professor, The Desmond Tutu HIV Centre (South Africa) Zimbabwe
Sanjay Bhagani Consultant Physician, Royal Free London NHS Trust and University College London (United
Kingdom)
Kenya
Darren Brown Physiotherapist, Chelsea and Westminster NHS Foundation Trust (United Kingdom) United Kingdom
Graham Brown Associate Professor and Director of Research and Evaluation, Centre for Social Impact, University
of New South Wales (Australia)
Australia
Susan Buchbinder Director, Bridge HIV, San Francisco Department of Public Health (United States) United States
Carlos Caceres Professor of Public Health and Director, Center for Research in Sexuality, AIDS and Society,
Universidad Peruana Cayetano Heredia (Peru)
Peru
Pedro Cahn Scientific Director, Fundacion Huesped (Argentina) Argentina
Patrizia Carrieri Epidemiologist, Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la
Santé & Traitement de l’Information Médicale, ISSPAM (France)
Italy
Georgina Caswell Head of Programmes, GNP+ (South Africa) Ghana
Graham Cooke Professor, Imperial College London (United Kingdom) United Kingdom
Antonella d’Arminio Monforte Professor of Infectious Diseases, University of Milan (Italy) Italy
Nikos Dedes Chair, Positive Voice (Greece) Greece
Julia del Amo Director, National Plan on AIDS, Ministry of Health (Spain) Spain
Richard Elliott Executive Director, HIV Legal Network (Canada) Canada
Wafaa M El-Sadr Professor, ICAP at Columbia University (United States) Egypt
María José Fuster-Ruiz de
Apodaca
Executive Director, Spanish AIDS Interdisciplinary Society (SEISIDA) (Spain) Spain
Giovanni Guaraldi Associate Professor, Modena HIV Metabolic Clinic - Università degli studi di Modena e Reggio
Emilia (Italy)
Italy
Tim Hallett Professor, Imperial College London (United Kingdom) United Kingdom
Richard Harding Professor, King’s College London (United Kingdom) United Kingdom
Margaret Hellard Professor and Deputy Director, Burnet Institute (Australia) Australia
Shabbar Jaffar Professor, Liverpool School of Tropical Medicine (United Kingdom) Pakistan
Meaghan Kall Principal Epidemiologist, Public Health England (United Kingdom) United States
Adeeba Kamarulzaman Professor of Medicine, University of Malaya; International AIDS Society (IAS) President (Malaysia) Malaysia
Marina Klein Professor of Medicine, McGill University Health Centre Research Institute (Canada) Canada
Jeffrey V Lazarus Professor, Barcelona Institute for Global Health (Spain) United States
Sharon R Lewin Director, The Peter Doherty Institute for Infection and Immunity (Australia) Australia
Ken Mayer Professor, Fenway Health and Harvard Medical School (United States) United States
Pepe Pérez Molina Attending Physician, Infectious Diseases Department, Hospital Universitario Ramón y Cajal (Spain) Spain
Doreen Moraa Communication Executive, ESA YOUTH 2030 (Kenya) Kenya
Denise Naniche Research Professor, Barcelona Institute for Global Health (Spain) France
Denis Nash Distinguished Professor of Epidemiology, City University of New York Graduate School of Public
Health and Health Policy (United States)
United States
Teymur Noori Expert HIV, European Centre for Disease Control and Prevention (Sweden) Sweden
Anton Pozniak Consultant Physician, Chelsea and Westminster NHS Foundation Trust and London School of
Hygiene and Tropical Medicine (United Kingdom)
United Kingdom
Reena Rajasuriar Associate Professor, University of Malaya (Malaysia) Malaysia
Peter Reiss Professor of Medicine, Amsterdam University Medical Centers, University of Amsterdam
(Netherlands)
Ethiopia
Nesrine Rizk Assistant Professor, American University of Beirut (Lebanon) Lebanon
Jürgen Rockstroh Head of Infectious Diseases, University Hospital Bonn (Germany) Germany
Caroline Sabin Professor, University College London (United Kingdom) United Kingdom
Kelly Safreed-Harmon Researcher, Barcelona Institute for Global Health (Spain) United States
David Serwadda Professor, Makerere University School of Public Health (Uganda) Uganda
Laura Waters Consultant Physician in Sexual Health and HIV, Central and North West London NHS Trust
(United Kingdom)
United Kingdom
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Disease-specific approaches to the provision of health services
for PLHIV are likely to be inefficient, particularly because it is
common for multiple comorbidities to share the same risk
factors, resulting in syndemics50. Integrated healthcare models
tailored to reflect the multimorbidity-related needs of PLHIV in
different geographical settings have the potential to deliver better
health outcomes, if implemented equitably51, and can do so cost-
effectively52. By addressing the prevention, screening, and
management of comorbidities in a person-centered manner,
guided by the needs of individual patients, health systems can also
respond flexibly to the multidimensional process of aging with
HIV, taking into account both chronic and episodic health-
related needs53. The priorities of PLHIV may differ from those of
service providers. For example, PLHIV may be more concerned
than providers about issues such as pain and sleep disturbance54.
Addressing concerns identified by PLHIV will be important for
effective treatment and symptom management.
A new paradigm is needed for addressing multimorbidity in
PLHIV. The conceptualization of frailty in geriatric healthcare
suggests a framework for identifying PLHIV who are at higher
risk of poor health outcomes55. WHO’s conceptualization of
healthy aging as a process that is influenced by both intrinsic
capacity and the environment may also provide insights, along
with the related concept of functional ability, which emphasizes
people’s ability to do what is important to them at different stages
of their lives55,56. Further research is needed to determine how
these approaches can inform the clinical care of PLHIV.
Health-related quality of life. Health is defined by WHO as “a
state of complete physical, mental and social well-being and not
merely the absence of disease or infirmity”57, while international
law recognizes the human right of all persons to “enjoyment of
the highest attainable standard of physical and mental health”
and requires States to take measures to progressively realize this
right over time58. HRQoL is increasingly acknowledged as an
important aspect of health. It is commonly assessed by patient-
reported outcome measures (PROMs), which reflect people’s
subjective perceptions of their health-related experiences59.
Validated PROMs can be used to systematically quantify people’s
HRQoL, allowing for observations about how HRQoL varies
among individuals, across groups, and over time. The compre-
hensive multidimensional nature of PROMs that measure
HRQoL makes them a useful tool for determining how well
people are responding to the challenges associated with complex
chronic health conditions. Incorporating HRQoL monitoring into
clinical and community services for PLHIV can provide a person-
centered perspective on the effectiveness of interventions, inform
health-related decision-making, and identify PLHIV who would
benefit from clinical and community services to address modifi-
able factors that negatively affect HRQoL.
The relevance of HRQoL as a measure of well-being among
PLHIV is well-established. PLHIV have reported poorer
HRQoL when compared to members of the general population,
and also poorer HRQoL than people with other chronic health
conditions3–5. Poorer HRQoL scores are closely correlated with
worse clinical health measures such as low CD4 T-cell count
and the occurrence of AIDS-defining events60–63. While
comorbidities, disability, and pain impair HRQoL7,64–66,
successful HIV treatment has a positive impact67,68. Physical
and mental dimensions of HRQoL scores predict viral rebound
and all-cause hospitalization69. Better scores on the physical
dimension of HRQoL predict survival among PLHIV receiving
ART, as well as emergency department utilization and hospital
discharge rates70,71. Enhancing HRQoL has the potential to
improve clinical outcomes, adherence, and retention in care7,60.
PLHIV report a number of components of HRQoL that are
important to them. These include physical (e.g., pain and
gastrointestinal issues), cognitive (e.g., memory and sleep),
psychological (e.g., anxiety and depression), social (e.g.,
isolation and intimacy), functional (e.g., independence and
ability to perform everyday activities), welfare (e.g., finances
and fears regarding immigration status), spiritual well-being
(e.g., achieving a sense of peace), and information (e.g., about
long-term outcomes about their condition) components72–74.
However, issues that are important to PLHIV, especially non-
physical issues, maybe missed by those providing routine
clinical care due to existing service delivery structures and a
lack of training about and awareness of these issues75. A
healthcare approach that focuses solely or primarily on
laboratory results may lead PLHIV to feel that the physical
and psychosocial concerns that matter to them are not equally
important to their healthcare providers76. Therefore, validated
PROMs used to measure HRQoL should reflect the symptoms
and concerns reported by PLHIV and should be culturally
appropriate, including for marginalized groups. Several inter-
nationally validated instruments, generic and HIV-specific, are
currently used to measure HRQoL in PLHIV for general
population comparisons, medico-economic assessments, and
specific research and clinical purposes (e.g., SF-12v2, MOS-
HIV, PROQOL-HIV, WHOQOL-bref)59. As both internalized
and enacted stigma negatively impact HRQoL77,78, some
validated instruments, such as PROQOL-HIV79, have included
a sub-scale measuring stigma as a component of HRQoL.
Potential benefits of using PROMs in routine HIV care have
been readily identified by PLHIV and their service providers:
achieving a person-centered approach, empowering individuals to
raise concerns, feeling that all concerns are heard and taken
seriously, facilitating discussion of sensitive problems, increasing
engagement with services and treatment adherence, and identify-
ing who is benefiting or not benefiting from care and support
strategies47.
HIV-related stigma and discrimination. PLHIV may experience
multiple forms of stigma and discrimination at various levels (e.g.,
policy and law, health system, and interpersonal) and in different















Other: public health 2
Other: health policy 2
Delphi process engagement
Round 1 survey 38
Round 2 survey 38
Expert Panel meeting 27
Round 3 survey 40
Participation in one or more
components
44
Mean # components engaged in 3.0
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Table 3 Consensus points on the role of health systems in advancing the long-term well-being of people living with HIV (PLHIV).
Point Grade A(%) SA(%) SD(%) D(%)
1. Framing a more comprehensive health agenda for people living with HIV (PLHIV)
1.1. PLHIV at all stages of their lives face unique health challenges. Therefore, health systems need to
provide comprehensive healthcare for PLHIV and focus on additional outcomes beyond virological
suppression.
U 100 0
1.2. The World Health Organization’s definition of health as “a state of complete physical, mental and social
well-being and not merely the absence of disease or infirmity” as well as the Sustainable Development Goal
of “[ensuring] healthy lives and [promoting] well-being for all at all ages” underscores the need for
healthcare paradigms that look beyond HIV-focused care to address the overall health and well-being of
PLHIV in an integrated, people-centered manner.
A 97.5 2.5
1.3. New clinical and public health targets are needed in all countries, regardless of economic status, in order
to optimize health system resources, achieve better health engagement, and improve health outcomes
in PLHIV.
A 95 5
1.4. Respecting, protecting, and fulfilling human rights is a necessary element of a strong, effective response
to HIV, and this approach should be embodied in all efforts to address the long-term health needs of PLHIV.
This approach encompasses attention to service delivery, structural inequalities, and laws, policies, and
practices that affect the health and well-being of PLHIV.
U 100 0
1.5. Actions to advance the health of PLHIV should be equitable, with consideration of the disproportionate
burden of HIV among key populations and of the intersectional nature of the stigma and discrimination
experienced by many members of these populations.
U 100 0
1.6. Efforts to improve healthcare for PLHIV should be aligned with efforts to expand universal health
coverage in accordance with the 2019 United Nations Political Declaration on Universal Health Coverage
and related global commitments.
U 100 0
1.7. In accordance with the Greater Involvement of People Living with HIV (GIPA) Principle and the World
Health Organization Framework on Integrated People-Centered Health Services, PLHIV should be




2.1. Both biological and non-biological factors put PLHIV at higher risk than people without HIV for a range
of health concerns, including infectious and non-communicable diseases, resulting in a greater
multimorbidity burden in PLHIV.
U 100 0
2.2. Mental health comorbidities are highly prevalent among PLHIV worldwide, along with physical health
comorbidities. They both warrant urgent attention from policy-makers and service providers.
U 100 0
2.3. Integrated approaches to multimorbidity prevention and management can reduce current health system
inefficiencies and facilitate greater engagement and retention in care.
A 97.5 2.5
2.4. Addressing multimorbidity as a component of comprehensive long-term care for PLHIV entails
considering issues reported by PLHIV to undermine their health-related quality of life (HRQoL), such as
pain, fatigue, sleep disturbance, and episodic and chronic disability.
U 87.5 12.5 0 0
2.5. Integrated, evidence-based, people-centered models of care for the prevention and management of
multiple conditions in PLHIV should provide multidisciplinary team care and effective referral to
psychosocial health services.
A 97.5 2.5
2.6. Global monitoring of national HIV responses with regard to comorbidities should include the collection
and reporting of disaggregated data for a range of infectious and non-communicable diseases.
A 97.5 2.5
2.7. In their HIV monitoring activities, national health systems should include not only comorbidities
specified in global HIV monitoring, but also other comorbidities that are relevant to their particular national
contexts.
U 100 0
2.8. Causes of mortality among PLHIV should be monitored at the national level using uniform coding for
comparative purposes.
A 97.5 2.5
2.9. Health system data on patterns of morbidity and causes of mortality in PLHIV should be published and
used to guide nationally targeted efforts to improve multimorbidity prevention and care in this population.
U 100 0
3. Self-reported health-related quality of life (HRQoL)
3.1. HRQoL is a central aspect of long-term health and well-being. Improving the HRQoL of PLHIV has the
potential to improve various outcomes including medication adherence, retention in care, and ultimately
clinical outcomes.
U 100 0
3.2. The effectiveness of healthcare for PLHIV should be assessed using more than biomedical outcomes.
Self-reported HRQoL should be recognized as a core outcome in the clinical management of individual
patients, as well as in national and global monitoring of health system responses to HIV.
U 100 0
3.3. The use of patient-reported outcome measures (PROMs) in clinical care for PLHIV has a number of
potential benefits, including achieving a person-centered approach; using health system resources more
efficiently; empowering PLHIV to raise concerns; facilitating discussion of sensitive problems; encouraging
greater engagement with services; and promoting treatment adherence.
A 97.5 2.5
3.4. Validated HIV-specific PROMS should be used to measure the HRQoL of PLHIV in clinical practice, with
findings informing efforts to address issues that are reported to be undermining HRQoL.
A 97.5 2.5
3.5. Health system monitoring of HRQoL should use both HIV-specific and non-HIV-specific validated
PROMs, with the latter enabling comparisons of the HRQoL of PLHIV to that of people without HIV.
U 100 0
3.6. HRQoL outcomes in PLHIV may be influenced by multifactorial causal pathways involving diverse
issues such as multimorbidity, frailty, symptom burden, disability, social isolation, financial insecurity, and
U 100 0
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settings (e.g., health sector, education, workplace, the justice
system, families and communities, and emergency and humani-
tarian settings)80. Such experiences have direct social and health
consequences (e.g., depression, anxiety, substance use, impaired
quality of life, social exclusion, internalized stigma)16. They also
adversely affect decisions regarding prevention behaviors,
engagement in care, and uptake of social services81–84.
Discriminatory laws that criminalize or otherwise punish key
populations, or that prohibit or impede the delivery of specific
health services (e.g., affordable medications, harm reduction
services, drug dependence treatment, and sexual and reproductive
healthcare), or that fail to respect and protect human rights such
as privacy or autonomy in medical decisionmaking, constitute
major barriers to the successful implementation of models for
comprehensive care for PLHIV85. Legal and policy frameworks
also can harm the material well-being of PLHIV when social
security programs do not adequately support those experiencing
disability related to HIV or comorbidities, or when HIV or
comorbidity services are not reimbursed, resulting in catastrophic
health expenditure86.
These examples underscore the role of HIV-related stigma as a
major driver of health inequities87. The stigma associated with
real or perceived HIV status, including within healthcare settings,
also intersects with other forms of stigma and discrimination
related to social identities or characteristics, e.g., race, ethnicity,
sexual orientation, gender identity, age, disability, poverty,
migrant status, sex work, drug use, and prior or current
incarceration15,88. This intersectional stigma can adversely affect
physical and mental health outcomes15. Layered stigma intensifies
the intertwined stigma-discrimination-care relationship, which
may lead to delayed, sub-optimal, or avoided care81,82. The
overload caused by suffering intersectional stigmas has adverse
effects on both mental health and health behaviors. This means
that the health, economic, and social needs of PLHIV suffering
structural inequality must be viewed through the prism of
intersectionality if there is to be a reduction in the cognitive,
social, physical, and moral distancing these groups experience
from that of other people89.
Examples of stigma and discrimination reported by PLHIV
in healthcare settings include excessive infection control
precautions taken by providers, longer waiting times, dis-
respect, negligence, reduced confidentiality, delay or denial of
treatment, and poor support services90. Two mechanisms act in
synergy: reduced care-seeking behaviors for fear of experien-
cing stigma and discrimination, and the stigmatizing and
discriminatory actions of healthcare staff. Secondary stigma,
arising from providing care to stigmatized groups, can also
affect health providers and modify their attitudes90. PLHIV
with multimorbidity may be treated in services where HIV-
related stigma could be compounded by additional stigma
associated with specific comorbidities (e.g., depression or liver
cancer84) or through lack of experience with PLHIV. Specific
integrated or shared care models incorporating specialists in
HIV and other staff, and the development of HIV-friendly
practices, are promising approaches to providing person-
centered, continuous care91,92.
Table 3 (continued)
Point Grade A(%) SA(%) SD(%) D(%)
HIV-related stigma and discrimination, indicating a need for comprehensive, evidence-based, people-
centered healthcare models.
3.7. PROMs that capture information about symptoms should be incorporated into HIV clinical care to
support patients’ involvement in their own care and to improve recognition of symptoms and problems that
may have a negative impact on health and well-being, such as undiagnosed comorbidities or social issues.
U 100 0
4. Stigma and discrimination
4.1. HIV-related stigma and discrimination, including discriminatory laws, as well as the social environment
fostered by these laws, constitute major barriers to the successful implementation and uptake of
comprehensive care models for PLHIV.
U 85 15 0 0
4.2. Negative consequences of HIV-related stigma and discrimination include reluctance to use health
services, medication non-adherence, internalized stigma, depression, emotional distress, social exclusion,
and poor HRQoL.
U 100 0
4.3. Promoting the holistic well-being of PLHIV in clinical and community care settings requires efforts to
identify specific ways in which stigma and discrimination affect PLHIV and to respond with interventions at
the service delivery, health system, and structural levels.
U 100 0
4.4. Effectively countering HIV-related stigma and discrimination requires actions to address its
intersectional nature. This means taking into account how HIV status and HIV risk intersect with other
factors that may elicit stigma and discrimination, such as age, sexual orientation, gender identity, sex
characteristics, race, religion, ethnicity, indigenous status, national origin, migrant status, drug use,
disability, incarceration, and sex work.
U 97.5 2.5 0 0
4.5. HIV-related stigma and discrimination are consistently reported in healthcare settings worldwide and
present major barriers to service uptake, service delivery, and retention in care, including for non-HIV-
specific health needs. This limits the effectiveness of integrated service delivery models that are essential
for advancing the overall health and well-being of PLHIV.
U 100 0
4.6. Countering HIV-related stigma and discrimination in healthcare settings requires expanding the
evidence base regarding how to effectively address the root causes of these problems and scaling up
interventions shown to achieve lasting improvements.
A 97.5 2.5
4.7. All types of healthcare settings should provide patients with information about their rights and should
have formal, confidential channels for reporting stigmatizing and discriminatory behaviors and experiences.
There should also be mechanisms for redress when violations of human rights have occurred.
U 100 0
4.8. Validated instruments should be utilized to monitor progress toward the achievement of global and
national HIV-related stigma and discrimination targets.
U 100 0
Consensus point response categories: A= agree; SA= somewhat agree; SD= somewhat disagree; D= disagree. In the third round (R3) of data collection, three points (2.4, 4.1, and 4.4) retained the 4-
point Likert-type scale response categories, while all other points were assessed using the binary response options of agree/disagree.
Grading of consensus responses: U= unanimous (100%) agreement (A+ SA); A= 90% to 99% agreement.
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Given the pervasiveness of stigma and discrimination directed
at PLHIV in healthcare settings, it is crucial to monitor this
experience using validated measures. HRQoL instruments
including a stigma dimension (e.g., PROQoL)79 may provide an
option for data collection of routine patient-reported outcomes.
Some validated instruments, such as the People Living with HIV
Stigma Index 2.093 and the HIV Stigma Scale94, which have been
validated in various settings around the world with support from
PLHIV, monitor longitudinal trends of experienced stigma59.
These could be complemented with measures of stigma expressed
by healthcare providers95–98.
Interventions to counter HIV-associated stigma should also be
implemented99,100. Such interventions have been
evaluated15,101–103 and can be categorized as: information-based,
structural, biomedical, skill-building, empowerment-based, and
contact-centered98. Interventions may be patient-focused or
provider-focused, and it is possible that optimal impact may be
achieved when combinations of interventions are employed.
However, further evidence on the effectiveness of such interven-
tions is needed. At a minimum, all types of healthcare settings
should provide PLHIV with information about their human
rights and a channel for reporting behaviors and policies that are
discriminatory or otherwise infringe upon rights in this setting.
Discussion
While continuing to press for the crucial goal of equitable uni-
versal access to ART, health systems must also expand the focus
of HIV care. This broader approach will enable PLHIV to
experience optimal long-term well-being, consistent with the
realization of the human right to enjoy the highest attainable
standard of physical and mental health. With this goal in mind,
the multidisciplinary expert panel developed this consensus
statement on the role of health systems in advancing the long-
term well-being of PLHIV. The process resulted in 31 items with
which expert panel members expressed high levels of agreement.
The consensus statement reflects the current state of knowledge
about health-related challenges for PLHIV in the key domains of
multimorbidity, HRQoL, and stigma and discrimination, as well
as addressing psychosocial needs associated with these issues.
Proposed measures for improving the long-term health outcomes
of PLHIV build on key principles in the fields of HIV and global
health, including principles expressed in the Constitution of the
World Health Organization57, the 2030 Agenda for Sustainable
Development104, the United Nations Political Declaration on
Universal Health Coverage105, and the WHO Framework on
Integrated, People-Centered Health Services106. This consensus
statement and the associated recommendations for action have
Box 1 | Key concepts
Health-related quality of life (HRQoL)–a construct that reflects an individual’s perceptions of his or her well-being in health-related aspects of life, with
the concept of health understood to encompass physical, mental, and social dimensions123,124. While there is a lack of consensus regarding how HRQoL
should be defined, instruments that measure HRQoL commonly address multiple aspects of physical, mental, and social well-being, such as mobility,
pain, anxiety, depression, social functioning, and vitality124.
Health system–as defined by the World Health Organization, “all organizations, people and actions whose primary intent is to promote, restore or
maintain health…. A health system is, therefore, more than the pyramid of publicly owned facilities that deliver personal health services. It includes, for
example, a mother caring for a sick child at home; private providers; behavior change programmes; vector-control campaigns; health insurance
organizations; occupational health and safety legislation125.”
HIV-related discrimination–as defined by UNAIDS, “the unfair and unjust treatment (act or omission) of an individual based on his or her real or
perceived HIV status. Discrimination in the context of HIV also includes the unfair treatment of other key populations, such as sex workers, people who
inject drugs, men who have sex with men, transgender people, people in prisons and other closed settings and, in some social contexts, women, young
people, migrants, refugees, and internally displaced people…. Discrimination can be institutionalized through existing laws, policies and practices that
negatively focus on people living with HIV and marginalized groups, including criminalized populations99.”
HIV-related stigma–as defined by UNAIDS, “the negative beliefs, feelings, and attitudes towards people living with HIV, groups associated with people
living with HIV (e.g., the families of people living with HIV) and other key populations at higher risk of HIV infection, such as people who inject drugs,
sex workers, men who have sex with men and transgender people99.”
Integrated health services–as defined by the World Health Organization, “health services that are managed and delivered so that people receive a
continuum of health promotion, disease prevention, diagnosis, treatment, disease-management, rehabilitation, and palliative care services, coordinated
across the different levels and sites of care within and beyond the health sector, and according to their needs throughout their life course126.”
Internalized stigma–an “individual’s personal acceptance” of the stigma associated with their stigmatized identity127.
Intersectional stigma and discrimination–a concept “characterize[d by] the convergence of multiple stigmatized identities within a person or group128”
and discussed by the UNAIDS Global Partnership for Action to Eliminate All Forms of HIV-related Stigma and Discrimination as, “fueled by multiple
factors, including their HIV or another health status, age, sex, gender identity, sexual orientation, race, disability, ethnicity, drug use, migration
status, etc80.”
Key populations–as defined by the World Health Organization, “groups who, due to specific higher-risk behaviors, are at increased risk of HIV
irrespective of the epidemic type or local context. Also, they often have legal and social issues related to their behaviors that increase their vulnerability
to HIV.” The five key populations widely addressed in the global response to HIV are men who have sex with men; people who inject drugs; people in
prisons and other closed settings; sex workers; and transgender people129.
Multimorbidity–the coexistence of multiple (somatic and/or mental) health conditions in addition to HIV.
People-centered care–as defined by the World Health Organization, “an approach to care that consciously adopts individuals’, carers’, families’ and
communities’ perspectives as participants, and beneficiaries of, trusted health systems that are organized around the comprehensive needs of people
rather than individual diseases, and respects social preferences. People-centered care also requires that patients have the education and support they
need to make decisions and participate in their own care and that carers are able to attain maximal function within a supportive working environment.
People-centered care is broader than patient and person-centered care, encompassing not only clinical encounters but also including attention to the
health of people in their communities and their crucial role in shaping health policy and health services126.”
Psychosocial health services–As defined by the US Institute of Medicine, “psychological and social services and interventions that enable patients, their
families, and health care providers to optimize biomedical health care and to manage the psychological/behavioral and social aspects of illness and its
consequences so as to promote better health130.”
Vulnerable populations–As defined by the World Health Organization, “groups of people who are particularly vulnerable to HIV infection in
certain situations or contexts, such as adolescents (particularly adolescent girls in sub-Saharan Africa), orphans, street children, people with disabilities
and migrant and mobile workers. These populations are not affected by HIV uniformly across all countries and epidemics129.”
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Box 2 | Organizations endorsing the HIV consensus statement to date
Organization Location
Adhara Asociación VIH/SIDA Spain
AFEW International Global
AIDES France
AIDS Action Europe Europe
AIDSImpact United Kingdom
Association de Lutte Contre le Sida (ALCS) Morocco
Australian Federation of AIDS Organisations Australia
Barcelona Institute for Global Health (ISGlobal) Spain
The British HIV Association United Kingdom
Burnet Institute Australia
Canadian HIV Trials Network, The Canadian Institutes of Health Research Canada
Canadian International HIV Rehabilitation Research Collaborative (CIHRRC) Canada
Central Africa International Epidemiology Databases to Evaluate AIDS (CA-IeDEA) Central Africa
Centre for Social Impact, University of New South Wales Australia
Children’s HIV Association United Kingdom and Ireland
City University of New York Graduate School of Public Health and Health Policy United States
City University of New York Institute for Implementation Science in Population Health (CUNY ISPH) United States
Country Coordination Mechanism - Tunisia, The Global Fund Tunisia
The Desmond Tutu Health Foundation South Africa
Deutsche AIDS Hilfe Germany
Deutsche Arbeitsgemeinschaft niedergelassener Ärzte in der Versorgung HIV-Infizierter Germany
East Europe and Central Asia Union of People Living with HIV (ECUO) Europe and Asia
Elton John AIDS Foundation Global
European AIDS Clinical Society Europe
European AIDS Treatment Group (EATG) Europe
Fenway Health United States
Frontline AIDS Global
Fundación Huésped Argentina
German AIDS Foundation Germany
German AIDS Society Germany
Global Network of People Living with HIV (GNP+) Global
Global Network of Young People Living with HIV (Y+ Global) Global
Grupo de Estudio del SIDA-SEIMC (GESIDA) Spain
Harvard University Center for AIDS Research United States
The HIV Justice Network The Netherlands
HIV Legal Network Canada
HIV Outcomes Europe
ICAP at Columbia University United States
Italian Cohort of Antiretroviral Naïve Patients (ICONA) Foundation Italy
Institute of HIV Research and Innovation Thailand
The Institute of Social and Preventive Medicine (ISPM), University Bern Switzerland
The International AIDS Society (IAS) Global
International Association of Providers of AIDS Care (IAPAC) Global
International Community of Women Living with HIV (ICW) Global
International Planned Parenthood Federation (IPPF) Global
The Italian Conference on AIDS and Antiviral Research Italy
Kasr Al-Aini HIV and Viral Hepatitis Fighting Group Egypt
Malaysian AIDS Council Malaysia
National Agency for Research on AIDS and Viral Hepatitis (ANRS) - Emerging Infectious Diseases France
National AIDS Trust United Kingdom
National Association of People with HIV Australia (NAPWHA) Australia
National Minority AIDS Council (NMAC) United States
NCD Alliance Global
The Peter Doherty Institute for Infection and Immunity Australia
Positive Voice Greece
Realize Canada
Rehabilitation in HIV Association (RHIVA) United Kingdom
Southern Africa International Epidemiology Databases to Evaluate AIDS (SA-IeDEA) Southern Africa
Spanish AIDS Interdisciplinary Society (SEISIDA) Spain
Stichting hiv monitoring (SHM) The Netherlands
STOPAIDS Global
Terrence Higgins Trust United Kingdom
TREAT Asia, the Foundation for AIDS Research (amfAR) Thailand
Treatment Action Group United States
UNITE Global Parliamentarians Network to End Infectious Diseases Global
Universidad Peruana Cayetano Heredia Peru
West Africa International Epidemiology Databases to Evaluate AIDS (WA-IeDEA) West Africa
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the potential to improve the well-being of PLHIV throughout
their lives.
It has long been recognized that respecting, protecting, and
fulfilling human rights can yield better health outcomes for
PLHIV49, yet human rights are contested in ways that undermine
many aspects of the HIV response worldwide. As health systems
focus more on the long-term care needs of PLHIV, it is
imperative to address the human rights challenges that under-
mine this effort. Discrimination against PLHIV in healthcare
settings is one of many such issues that warrant urgent
attention80. While some matters are determined by actors outside
of health system institutions (e.g., lawmakers adopting laws that
regulate certain aspects of how health systems operate and how
services are delivered), it is within the power and purview of
health system actors (institutions and individuals) to influence
many structural factors so as to reduce discrimination and other
barriers. Therefore, health systems and the people who work
within them must recognize and work to eliminate the multiple
forms of structural discrimination that undermine the health of
PLHIV. They have an important vantage point as observers of the
consequences of such barriers for health and HRQoL and an
influential position as advocates, with considerable moral and
political persuasion. They also bear responsibility for removing
such barriers within healthcare settings, for example by pro-
moting initiatives to hire diverse and inclusive workforces,
establishing systems to report and investigate discrimination, and
providing health services in geographical locations and at times
that will facilitate access for marginalized or vulnerable popula-
tions. A pervasive and highly problematic form of structural
discrimination is HIV criminalization (i.e., the unjust application
of criminal law to people living with HIV based solely on their
HIV status), alongside the criminalization and stigmatization of
various activities associated with HIV risk107. Other relevant and
pressing human rights issues include privacy and confidentiality,
personal autonomy, access to justice, and meaningful participa-
tion in health decisionmaking108.
Meaningful participation can be advanced by including PLHIV
in the development and enactment of policy and programmatic
responses, as called for by the widely endorsed Greater Involve-
ment of People Living with HIV Principle109. PLHIV have unique
insight into the factors that positively and negatively affect their
well-being. Their perspectives are essential in the formulation of
effective strategies both at the policy and the service delivery
levels110. The 2021 United Nations Political Declaration on HIV
and AIDS called for the expansion of community-led HIV service
delivery to comprise at least 30% of testing and treatment-related
services by 2025111. This target is even more important in the
context of improving the long-term health-related outcomes of
PLHIV. Community-based health and psychosocial service pro-
viders can do more than supplement government and private
services; they also are well-suited to identify innovative and cost-
effective models of care and to engage marginalized and vulner-
able populations19,110. Efforts to address the needs of PLHIV in
relation to multimorbidity, HRQoL, and stigma and discrimina-
tion can be greatly enhanced through the involvement of com-
munities in setting the research and programmatic agendas, as
well as in direct service delivery; such activities need to be sus-
tainably supported and financed.
Evidence suggests that living long-term with HIV can bring
episodic functional concerns112. Continuous assessment in rou-
tine care is essential for anticipation, detection, and management
of fluctuating concerns. Such care should include HRQoL mea-
sures that take a multidimensional approach, reflecting what
matters to PLHIV, including concerns such as stigma and social
function72,113. For self-reported HRQoL outcomes to inform care
delivery in a more person-centered manner, health systems and
service organizations must pay careful attention to language,
culture, and local and individual priorities regarding well-being.
Data should be collected and used within a meaningful patient-
provider relationship in order to optimize validity and
reliability114. This has been achieved even in resource-limited
settings with poor literacy and advanced HIV infection115.
Locally developed systems in Africa, for example, have enabled
patients to self-report using a “hand-scoring” system116. Other
systems support community caregivers of people with cancer and
HIV in India and African countries to collect self-reported patient
outcomes using mHealth, providing data directly to a provider
“dashboard” to inform the allocation of staff resources to those
most in need117. A growing body of evidence indicates that ser-
vice delivery approaches to HIV care can incorporate attention to
patient experiences and concerns in high-prevalence, low-
resource areas85,118.
The expert panel carried out its work with the understanding
that health systems vary substantially across, and often within,
countries. Patterns of multimorbidity likewise vary greatly across
geographical regions. Monitoring progress in the global HIV
response requires a set of standardized indicators of health
behaviors and comorbidities that contribute substantially to the
global multimorbidity burden119. To the extent that resources
allow, health systems are strongly encouraged to monitor these
behaviors and comorbidities and to solicit input from PLHIV on
additional national monitoring priorities1,120. Although many
national health systems are not currently monitoring HRQoL,
stigma, or discrimination among PLHIV, they should, at a
minimum, include indicators from the UNAIDS Global AIDS
Strategy 2021–2026, in order to standardize monitoring.
In its Global AIDS Strategy, UNAIDS set ambitious 2025 tar-
gets. It established 10 result areas that broadly aim to achieve
equitable access to fully-resourced and integrated HIV services
for all people living with or at risk of HIV. Priority actions, which
support the targets and result areas, are generally aimed at
national governments, though nearly all require support from
non-government stakeholders. While priority actions may vary
by geographic region, even in the context of limited resources, our
consensus statement offers concrete recommendations regarding
multimorbidity, HRQoL, and stigma and discrimination that all
health systems should aspire to implement. The consensus points
and next steps (Box 3) articulate the direction in which healthcare
for PLHIV should evolve in all countries, emphasising that a
reorientation of health systems will necessarily be incremental.
The expert panel also recognises that the evidence base under-
pinning its conclusions is limited in some ways but rapidly
growing. Thus the consensus statement should be regarded as an
initial articulation of a transformational process, to be refined as
stakeholders in government, civil society, research, healthcare and
the social and legal sectors deepen their understanding of how
health systems can support PLHIV in achieving optimal well-
being.
Across the three Delphi rounds, three consensus points (2.4,
4.1, and 4.4) generated lower overall agreement than the others.
This was reflected in our decision to continue to evaluate them on
a four-point Likert scale in the third Delphi round instead of the
binary agree/disagree measurement used with the other points.
The results from that round revealed a continued, relatively lower
level of agreement for two of the statements (2.4 and 4.1)
(Table 3). The lack of unanimity here may highlight a lack of
consensus among different types of stakeholders in the broader
HIV field regarding whether some issues (e.g., pain) should be
prioritized in health system efforts to improve health
outcomes for PLHIV. It may also reflect the lack of shared con-
ceptual frameworks for other issues such as stigma and dis-
crimination, punitive laws, and intersectionality, pointing to a
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possible need to engage a wider range of stakeholders in dialog
about these issues.
Limitations and strengths. The Delphi process involving a virtual
expert panel enables the systematic gathering of the collective
knowledge and recommendations of leaders in the field while
separated by physical distances27,121. However, this process has
both limitations and strengths. Typical of the Delphi method, the
research team used purposive sampling to recruit potential expert
panel members from existing HIV networks. The initial roster was
then expanded using snowball sampling to include a wider range of
experts and, potentially, viewpoints. The use of English in con-
ducting the study may have restricted the composition of the expert
panel and, by extension, the study outputs. The size of Delphi
panels can range widely. This study included 44 individuals, which
is within the 10 to 50 generally recommended for expert panels122.
Members were from 22 countries across the six WHO regions. We
note that 25% of them worked in a country different from their
country of origin and speculate that their assessment of consensus
points may have benefitted from their diverse backgrounds. How-
ever, this also meant that in the case of Africa, with its dis-
proportionate burden of HIV, two of the six African members no
longer worked on the continent. Thus, it is not clear to what extent
they considered the African context in their assessment of con-
sensus points. That the composition of the panel reflected activities
spanning research, service provision, community-based care, policy,
and advocacy provided the project with expertise and knowledge
regarding the priorities of diverse stakeholder groups.
An advantage of using scoping reviews for the three domains is
that expert panel members could draw on their knowledge and
experience to focus on issues that pertain to improving the well-
being of PLHIV but may not yet be extensively documented in
the peer-reviewed or gray literature. A further strength of the
study was the collection of open-ended (text-based) comments
from respondents who agreed with statements (e.g., for further
input and suggested edits), as well as from respondents who
disagreed (e.g., to understand their rationale and suggested
changes). This elicitation and incorporation of feedback from
respondents across all three survey rounds (with high response
rates, i.e., R1, R2= 86%; R3= 91%) and the online meeting were
likely critical to the consistent increase in levels of agreement.
Finally, the worldwide relevance of the expert panel’s
consensus is suggested by the fact that the consensus statement
had been endorsed by 67 organizations (Box 2) at the time this
article went to press.
Conclusion
Prevention and treatment of HIV infection including access to
ART remain a major public health and human rights challenge
that requires urgent, sustained attention. This consensus state-
ment addresses the concurrent role of health systems in advan-
cing the long-term well-being of PLHIV. Multimorbidity,
HRQoL, and stigma and discrimination continue to be major
issues for PLHIV, including those who have achieved viral sup-
pression and in particular those from marginalized populations.
The consensus statement was prepared by a large multi-
disciplinary panel of experts representing the interests of a diverse
range of stakeholders including HIV community members. Its
purpose was to facilitate consensus on major health-related issues
affecting PLHIV to be addressed from a patient-centered per-
spective, noting that many issues are not captured in current HIV
monitoring processes and guidelines. While additional research is
needed, the burden of creating new, simple, standardized indi-
cators for insufficiently addressed issues will largely fall on
international bodies such as WHO and UNAIDS, both of which
have mechanisms for community consultation and engagement.
This process will require a strong commitment from all Member
States, which must report on the indicators and implement
policies to enhance health system performance. We encourage
these organizations and national health system monitoring bodies
to continue to take on this task, to report at regular intervals, and
to meaningfully involve PLHIV, even when additional costs are
involved. PLHIV and civil society organizations should also play a
role in reporting ways in which governments are not meeting
their obligations. Ultimately, a concerted effort by all stakeholders
is required to ensure the long-term well-being of the millions of
people around the world living with HIV and to end the HIV
pandemic.
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